黄斑変性症治療の世界市場レポート 2024

黄斑変性症治療の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.5%の年間複合成長率（CAGR）で169億9,000万米ドルに成長すると予想されます。予測期間で予想される成長は、調査の進歩、ヘルスケア費の増加、罹患率の上昇、個別化医療アプローチ、視力の健康に対する世界の取り組みに起因すると考えられます。この期間に予想される主な動向としては、神経保護および再生療法への注目、遠隔医療および遠隔モニタリングの拡大、個別化医療へのアプローチ、幹細胞療法の研究、啓発および教育のための患者中心の取り組みなどが挙げられます。

網膜疾患の増加により、黄斑変性症治療市場の成長が促進されると予想されます。網膜障害は重要な組織に影響を及ぼし、視覚情報の処理を妨害し、視覚の歪みや障害を引き起こす可能性があります。米国眼科学会によると、2050年までに米国の約732万人が原発開放隅角緑内障（一連の眼疾患の総称）に罹患すると予測されています。この症状は、70～79歳（32％）、女性（50％）、ヒスパニック系（50％）の間で最も蔓延すると予想されています。ヒスパニック系男性は影響を受ける最大の人口グループを代表します。その結果、網膜疾患の蔓延が黄斑変性症治療市場の拡大を促進しています。

高齢化人口の増加は、将来黄斑変性症治療市場の成長を促進すると予想されます。人口の高齢化とは、社会または人口における高齢者の割合の増加を特徴とする人口動態の変化を指します。 黄斑変性症治療は、網膜の中心部に影響を与える症状に焦点を当て、高齢者における視覚障害を対象としています。たとえば、世界保健機関は2022年 10月に、2030年までに世界の6人に1人が60歳以上になると予測しました。この期間中に、60歳以上の人口の割合は2020年の10億人から14億人に増加すると予想されています。さらに、世界の60歳以上の個人人口は2倍に増加し、2050年までに21億人に達すると予想されています。したがって、高齢化人口の増加が黄斑変性症治療市場を推進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の黄斑変性症治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 滲出性黄斑変性症
• 乾性黄斑変性症
• 世界の黄斑変性症治療市場、疾患段階別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 初期AMD
• 中期AMD
• 後期AMD
• 世界の黄斑変性症治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 注射
• その他
• 世界の黄斑変性症治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 外来手術センター
• 眼科クリニック
• 病院

第7章 地域および国の分析

• 世界の黄斑変性症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の黄斑変性症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 黄斑変性症治療市場の競合情勢
• 黄斑変性症治療市場企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Allergan Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の主要および革新的な企業

• GlaxoSmithKline plc
• Panoptica
• Nidec Pharma Inc.
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Valeant Pharmaceuticals
• Arrys Therapeutics Inc.
• Santen Pharmaceuticals
• StemCells Inc.
• Aerie Pharmaceuticals Inc.
• BioXcel Therapeutics Inc.
• Regenxbio Inc.
• Spark Therapeutics Inc.
• Alimera Sciences Inc.
• Rxi Pharmaceuticals

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

The macula is the central part of the retina responsible for central vision. Age-related macular degeneration (AMD) is a common condition in individuals over 60, resulting in the degeneration of the macula and causing distortion or loss of central vision. Treatment aims to slow the progression of the disease and prevent severe vision loss.

The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

The macular degeneration treatment research report is one of a series of new reports from The Business Research Company that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $9.74 billion in 2023 to $10.99 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. Historical growth can be attributed to an aging population, lifestyle changes, limited treatment options, increased awareness, and the development of healthcare infrastructure.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, and global efforts for vision health. Major trends expected in this period include a focus on neuroprotection and regeneration therapies, the expansion of telemedicine and remote monitoring, personalized medicine approaches, the investigation of stem cell therapies, and patient-focused initiatives for awareness and education.

The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.

The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.

One prominent trend in the market for macular degeneration treatment is the advancement of cutting-edge therapies, which has garnered considerable attention. These therapies, such as gene therapy, have seen notable progress, particularly in tackling inherited retinal diseases. For example, in October 2021, Genentech, a US-based biotech firm, announced the FDA's approval of Susvimo, a new treatment for wet age-related macular degeneration (AMD). This approval represents a significant milestone as Susvimo becomes the first treatment for wet AMD to offer an alternative to the standard-of-care eye injections, which have been required as frequently as once per month over the last 15 years. Susvimo is designed to assist individuals with wet AMD in preserving their vision with as few as two treatments per year. This is accomplished through the continuous injection of medication into the eye via a refillable implant, indicating a major advancement in offering a more convenient treatment option for wet AMD patients.

Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.

In September 2021, Novartis, a pharmaceutical company based in Switzerland, acquired Arctos Medical for an undisclosed sum. This acquisition is anticipated to enable Novartis to develop treatments for individuals experiencing vision loss and capitalize on the promise of optogenetics as a foundation for effective therapies. Arctos Medical, located in Switzerland, specializes in creating intelligent medical devices and gene therapy strategies for eye-related diseases aimed at addressing blindness.

Major companies operating in the macular degeneration treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Panoptica, Nidec Pharma Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Valeant Pharmaceuticals, Arrys Therapeutics Inc., Santen Pharmaceuticals, StemCells Inc., Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Rxi Pharmaceuticals, Avita Therapeutics Ltd., Applied Genetic Technologies Corp. (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc., NanOcular Ltd., Codiak BioSciences Inc., Nightstar Therapeutics plc

North America was the largest region in the macular degeneration treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Macular Degeneration Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
• 2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
• 3) By Route of Administration: Oral; Injectable; Other Route of Administration
• 4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Allergan Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Macular Degeneration Treatment Market Characteristics

3. Macular Degeneration Treatment Market Trends And Strategies

4. Macular Degeneration Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Macular Degeneration Treatment Market Size and Growth

• 5.1. Global Macular Degeneration Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Macular Degeneration Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Macular Degeneration Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Macular Degeneration Treatment Market Segmentation

• 6.1. Global Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Wet Macular Degeneration
• Dry Macular Degeneration
• 6.2. Global Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Early-Stage AMD
• Intermediate AMD
• Late-Stage AMD
• 6.3. Global Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Injectable
• Other Route of Administration
• 6.4. Global Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Ambulatory Surgical Centers
• Ophthalmic Clinics
• Hospitals

7. Macular Degeneration Treatment Market Regional And Country Analysis

• 7.1. Global Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Macular Degeneration Treatment Market

• 8.1. Asia-Pacific Macular Degeneration Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Macular Degeneration Treatment Market

• 9.1. China Macular Degeneration Treatment Market Overview
• 9.2. China Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Macular Degeneration Treatment Market

• 10.1. India Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Macular Degeneration Treatment Market

• 11.1. Japan Macular Degeneration Treatment Market Overview
• 11.2. Japan Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Macular Degeneration Treatment Market

• 12.1. Australia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Macular Degeneration Treatment Market

• 13.1. Indonesia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Macular Degeneration Treatment Market

• 14.1. South Korea Macular Degeneration Treatment Market Overview
• 14.2. South Korea Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Macular Degeneration Treatment Market

• 15.1. Western Europe Macular Degeneration Treatment Market Overview
• 15.2. Western Europe Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Macular Degeneration Treatment Market

• 16.1. UK Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Macular Degeneration Treatment Market

• 17.1. Germany Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Macular Degeneration Treatment Market

• 18.1. France Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Macular Degeneration Treatment Market

• 19.1. Italy Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Macular Degeneration Treatment Market

• 20.1. Spain Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Macular Degeneration Treatment Market

• 21.1. Eastern Europe Macular Degeneration Treatment Market Overview
• 21.2. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Macular Degeneration Treatment Market

• 22.1. Russia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Macular Degeneration Treatment Market

• 23.1. North America Macular Degeneration Treatment Market Overview
• 23.2. North America Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Macular Degeneration Treatment Market

• 24.1. USA Macular Degeneration Treatment Market Overview
• 24.2. USA Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Macular Degeneration Treatment Market

• 25.1. Canada Macular Degeneration Treatment Market Overview
• 25.2. Canada Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Macular Degeneration Treatment Market

• 26.1. South America Macular Degeneration Treatment Market Overview
• 26.2. South America Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Macular Degeneration Treatment Market

• 27.1. Brazil Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Macular Degeneration Treatment Market

• 28.1. Middle East Macular Degeneration Treatment Market Overview
• 28.2. Middle East Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Macular Degeneration Treatment Market

• 29.1. Africa Macular Degeneration Treatment Market Overview
• 29.2. Africa Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Macular Degeneration Treatment Market Competitive Landscape And Company Profiles

• 30.1. Macular Degeneration Treatment Market Competitive Landscape
• 30.2. Macular Degeneration Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Allergan Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Macular Degeneration Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Panoptica
• 31.3. Nidec Pharma Inc.
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Bausch Health Companies Inc.
• 31.6. Valeant Pharmaceuticals
• 31.7. Arrys Therapeutics Inc.
• 31.8. Santen Pharmaceuticals
• 31.9. StemCells Inc.
• 31.10. Aerie Pharmaceuticals Inc.
• 31.11. BioXcel Therapeutics Inc.
• 31.12. Regenxbio Inc.
• 31.13. Spark Therapeutics Inc.
• 31.14. Alimera Sciences Inc.
• 31.15. Rxi Pharmaceuticals

32. Global Macular Degeneration Treatment Market Competitive Benchmarking

33. Global Macular Degeneration Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Macular Degeneration Treatment Market

35. Macular Degeneration Treatment Market Future Outlook and Potential Analysis

• 35.1 Macular Degeneration Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Macular Degeneration Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Macular Degeneration Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer